Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89118&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Altimmune, Inc. (ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89119&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming July 5, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 13, 2024, Kerrisdale Capital published a report alle.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)

NEW YORK, NY / ACCESSWIRE / July 3, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88970&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 investing in Altimmune stock or options between December 1, 2023 and April 26, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/ALT.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Clinical-state biopharmaceutical company Altimmune Inc. NASDAQ: ALT focuses on developing peptide-based therapeutics for obesity and chronic liver diseases, including non-alcoholic steatohepatitis (NASH). Their top candidate is a GLP-1/glucagon agonist called pemvidutide.

Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88900&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 – ALT

NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88893&wire=1 or contact Joseph E. Levi, Esq.

July 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against ALT

LOS ANGELES , July 2, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT).

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

Investors can contact the law firm at no cost to learn more about recovering their losses

Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 5, 2024 in Altimmune Lawsuit – ALT

NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88747&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will be hosting one-on-one meetings with institutional investors at the Leerink Partners Therapeutics Forum: I&I and Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The event will feature analyst-hosted panel discussions with leading physicians in a range of autoimmune and metabolic indications, as well as meetings between participating companies and investors.

Altimmune to Participate at Leerink Partners Therapeutics Forum

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, inclusive (the "Class Period").

IMMINENT ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or “the Company”) (NASDAQ: ALT) and certain of its officers.

ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88625&wire=1 or contact Joseph E. Levi, Esq.

July 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - ALT

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88612&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88609&wire=1 or contact Joseph E. Levi, Esq.

Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

The Gross Law Firm Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 – ALT

NEW YORK, NY / ACCESSWIRE / July 1, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88444&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT

NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) and certain officers.   The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALT

Altimmune is making medicines for obesity, just like Viking Therapeutics. Currently, it has a strong candidate in the works and enough cash on hand.

3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics

NEW YORK, NY / ACCESSWIRE / June 29, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=88251&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK , June 29, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors a shareholder filed a class action lawsuit on behalf of all purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between December 1, 2023 and April 26, 2024. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by July 5, 2024.

News for Altimmune Stock (ALT)